Zai Lab Stock

Zai Lab Dividend 2024

Zai Lab Dividend

0 USD

Zai Lab Dividend yield

Ticker

9688.HK

ISIN

KYG9887T1085

WKN

A2DX7H

How much dividend does Zai Lab 2024 pay?

According to the latest status from September 2024, Zai Lab paid a total of 0 USD per share in dividends within the last 12 months. With the current Zai Lab price of 2.32 USD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Zai Lab Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Zai Lab Dividend Safe?

Zai Lab has been increasing the dividend for 0 years.

Over the past 8 years, Zai Lab has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Zai Lab's Dividend Distributions

Zai Lab’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Zai Lab's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Zai Lab's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Zai Lab’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Zai Lab Aktienanalyse

What does Zai Lab do?

Zai Lab Ltd is a biotech company based in Shanghai, China, that focuses on the development and commercialization of innovative drugs and therapies for unmet medical needs. The company's history dates back to 2014 when Dr. Samantha Du, an experienced pharma executive, founded the company to realize her vision of a modern, science-based biotech company in China. Zai Lab's business model is based on several strategic pillars. On one hand, the company collaborates with leading pharma and biotech research centers to discover, develop, and market new active ingredients and therapies. On the other hand, Zai Lab also promotes the acquisition of promising companies and technologies to strengthen its innovative power and expand its product portfolio. Another important aspect of Zai Lab's business model is its close collaboration with the Chinese government and healthcare system to simplify and improve access to new drugs and therapies for patients in China. Zai Lab operates in various business areas and markets to cover a wide range of medical needs. One of Zai Lab's main areas is oncology pharmaceuticals used to treat cancer. The company has focused primarily on novel active ingredients that have the potential to selectively target certain types of cancer cells while sparing healthy cells. Zai Lab's key oncology products include Niraparib, a PARP inhibitor for the treatment of ovarian cancer, and ZL-2301, a SHRPI inhibitor for the treatment of liver and lung cancer. Another important business area for Zai Lab is immunology and autoimmunity. Here, the company develops new therapies and medications that can modulate and regulate the immune system in certain disease conditions. One of the most promising products is the drug FOLFIRINOX, an immunomodulator for the treatment of chronic inflammatory bowel diseases. In addition to oncology and immunology, Zai Lab is also involved in other areas of medicine such as gastroenterology, infectious diseases, and neuroscience. In these fields, the company develops new antibiotics, vaccines, and medications for the treatment of diseases such as hepatitis B, Lyme disease, and Alzheimer's. Overall, Zai Lab aims to improve the health and well-being of patients in China and worldwide through its broad product range and innovation power. In recent years, Zai Lab has written an impressive growth story. The company has raised several million dollars in investments since its inception and has built a strong network and collaboration with other companies. Recently, Zai Lab has also attracted additional investors through IPOs in Hong Kong and New York, further strengthening its position as a leading biotech company in China. Overall, Zai Lab is an emerging biotech company that aims to fulfill medical needs in China and worldwide with its broad range of products and services and its innovation power. The company relies on close collaboration with leading research centers, companies, and government agencies, and strives to improve the health and well-being of patients worldwide. Zai Lab is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Zai Lab stock

How much dividend does Zai Lab pay?

Over the past 12 months, Zai Lab paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Zai Lab is expected to pay a dividend of 0 USD.

What is the dividend yield of Zai Lab?

The current dividend yield of Zai Lab is .

When does Zai Lab pay dividends?

Zai Lab pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Zai Lab?

Zai Lab paid dividends every year for the past 0 years.

What is the dividend of Zai Lab?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Zai Lab located?

Zai Lab is assigned to the 'Health' sector.

Wann musste ich die Aktien von Zai Lab kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Zai Lab from 9/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Zai Lab pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Zai Lab in the year 2023?

In the year 2023, Zai Lab distributed 0 USD as dividends.

In which currency does Zai Lab pay out the dividend?

The dividends of Zai Lab are distributed in USD.

Andere Kennzahlen von Zai Lab

Our stock analysis for Zai Lab Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Zai Lab Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.